-51%

est. 2Y upside i

HealthcareAI & MLSeries D+

Rank

#3712

Sector

Medical Devices, Digital Health, AI

Est. Liquidity

~3Y

Data Quality

Data: Medium

AliveCor operates in a growing digital health market with recent positive FDA clearances for its advanced ECG systems.

Last updated: March 10, 2026

Bull (15%)+100%

Successful adoption of the Kardia 12L ECG system and new AI determinations drives significant expansion into healthcare provider segments and international markets. Revenue reaches $150M-$200M by 2028, justifying a $1.8B - $2B valuation (100% upside) at a similar or slightly higher multiple, leading to a successful IPO or strategic acquisition.

Base (45%)+20%

AliveCor maintains its market position with steady growth in Kardia device sales and KardiaCare subscriptions, despite competitive pressures. Revenue grows to $100M-$120M by 2028, leading to a modest valuation increase to $1.1B - $1.2B (20% upside) or an acquisition at a slight premium.

Bear (40%)-40%

Increased competition from large tech (Apple's continued dominance after lawsuit win) and established medical device companies, coupled with potential commoditization of basic ECG monitoring, limits growth. Slower adoption of new products and ongoing regulatory challenges lead to revenue stalling at $80M-$90M, resulting in a down round or acquisition at a reduced valuation of $550M - $600M (-40% downside), severely impacting common stock value due to liquidation preferences.

Est. time to liquidity~2.5 years

Preference Stack Risk

severe

Funding Intensity

37%

Investors hold $350M in liquidation preferences ahead of common stock, representing 37.1% of the current $944M valuation. In an exit at or below $350M, common shareholders would receive nothing.

Dilution Risk

moderate

As a Series F company, further funding rounds before an IPO are possible, leading to additional dilution for existing common shareholders.

Secondary Liquidity

limited

Secondary markets exist for accredited investors to buy and sell private shares, but liquidity is not guaranteed and is typically less active than public markets.

Other — 2 roles

View all 2 open roles at Alivecor →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Alivecor's data — designed to show you've done your homework.

  • 1

    “Given the recent legal outcomes with Apple, how is AliveCor strategizing to differentiate and grow its market share in the consumer wearable ECG space, particularly against dominant tech incumbents?”

  • 2

    “With the recent FDA clearances for the Kardia 12L and new AI determinations, what are the specific commercialization targets and go-to-market strategies for these advanced products over the next 12-24 months, and how will these impact the revenue growth trajectory?”

  • 3

    “AliveCor's Series F was in 2022, and there was significant funding in 2024. How does the company envision its path to a liquidity event (IPO or acquisition) within a 2-year horizon, and what are the key milestones for employees holding common stock to realize value?”

Community

Valuation Sentiment

Our model estimates -51% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.